<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5595278</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2016762211</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000004313</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>20</subject><subject>41</subject><subject>132</subject><subject>323</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Alemtuzumab CARE-MS I 5-year follow-up </plain></SENT>
</text></SecTag></article-title><subtitle>Durable efficacy in the absence of continuous MS therapy</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Havrdova</surname><given-names>Eva</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. Biogen 2. Novartis 3. Genzyme 4. Actelion 5. Celgene</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. European Commission Grant: ABIRISK - IMI (2012-2016), investigator 2. Czech Ministry of Education: PROGRES Q27/LF1 (2017- 2022), investigator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>Douglas L.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Adelphi, Acorda Therapeutics, Biogen, Genentech, Genzyme, Hoffman LaRoche, Medday, Novartis, Pfizer, Receptos, Roche, Sanofi-Aventis</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Genzyme, travel support</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Method of evaluating the efficacy of drug on brain nerve cells</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Biogen, Novartis</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>CIHR 15630 co-PI 2007 2012 CIHR 84360 co-PI 2007-2012 CIHR 84367 PI 2007-2012 CIHR 111169 coPI 2011-2014 CIHR 43871 co-PI 2010-2015 CIHR 377721 PI 2017-2020</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>International Progressive MS Alliance Multiple Sclerosis Research Foundation Stock/Stock Options, Medical Equipment &amp; Materials: NeuroRx Research, 2002-2013</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Jeffrey A.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Adamas 12/13/16 - Consulting Celgene 11/11/15, 6/12/17 - Consulting Genentech 7/31/15 - Consulting Genzyme/Sanofi 7/22/15 - Consulting Merck 6/10/16 - Consulting Novartis 5/13/15 - Steering Committee</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>2015-present, Co-Editor, Multiple Sclerosis Journal - Experimental, Translational and Clinical</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Cambridge University Press, JA Cohen and RA Rudick, eds, Multiple Sclerosis Therapeutics, 4th edition, 2011</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Department of Defense, PR093324, PI, 2010-14 NIH, 1 RO1 NS074787, 2011-4</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>National MS Society, PP1752, PI, 06/2012-11/2013 Consortium of MS Centers, FWA00005367, PI, 12/2012-11/2013</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hartung</surname><given-names>Hans-Peter</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Opexa; Octapharma; Receptos Celgene, Roche, Teva</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker Honoraria from: Biogen Idec Genzyme Teva Sanofi Aventis Merck Novartis Roche Bayer Healthcare</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>editorial board member (unpaid): , frontiers neurology / immunology; european journal of neurology; current opinion in neurology, nature reviews neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Edward J.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Acorda (2) Bayer, (3) Biogen, (4) EMD Serono, (5) Genentech Roche (6) Novartis, (7) Sanofi Genzyme, and (8) Teva</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Acorda, travel and speaker honoraria, (2) Biogen, travel and speaker honoraria (3) EMD Serono, travel and speaker honoraria, (4) Genentech Roche travel and speaker honoraria, (5) Novartis travel and speaker honoraria, (6) Sanofi Genzyme, travel and speaker honoraria, (7) Teva, travel and speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Commercial: (1) Bayer, (2) Biogen, (3) EMD Serono, (4) Genentech Roche (5) Novartis, (6) Sanofi Genzyme, and (7) Teva Neuroscience</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Acorda (2) Biogen, (3) EMD Serono, (4) Genetech Roche (5) Novartis, (6) Sanofi Genzyme, and (7) Teva</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Abbvie (2) Allergan (3) Biogen (4) Celgene (5) Chugai (6) EMD Serono, (7) Genentech Roche (8) Mallinkrodt (9) MedDay (10) Novartis, (11) Opexa (12) Sanofi Genzyme, (13) Teva Neuroscience and (14) TG Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Clinical Associate Professor, Dell Medical School University of Texas at Austin</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) National Multiple Sclerosis Society</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>Teva, Patent litigation expert testimony 2015-2016</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Giovannoni</surname><given-names>Gavin</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker honoraria: (1)Biogen-Idec (2) Genzyme (3) GW Pharma (4) Merck-Serono (5) Novartis (6) Roche (7) Teva</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Multiple Sclerosis and Related Disorders, Editor since 2011</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Novartis (2) Teva</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Genzyme 2012-2014 Merck 2012-2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Schippling</surname><given-names>Sven</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1.Bayer Healthcare 2.Biogen 3.Merck Serono 4.Novartis 5.Sanofi Genzyme 6.TEVA</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1.Bayer Healthcare, travel compensation, speaker honoraria 2.Biogen, travel compensation, speaker honoraria 3.Merck Serono, travel compensation, speaker honoraria 4.Novartis, travel compensation, speaker honoraria 5.Sanofi Genzyme, travel compensation, speaker honoraria 6.TEVA, travel compensation, speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Frontiers in Neurology, Associate Editor</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Therapeutic vaccination in PML using VP1 and IL7.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1. Sanofi Genzyme 2. Novartis</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. University of Zurich, Clinical Research Priority Program, Co-Director, 3 years</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1. Betty and David Koetser Foundation for Brain Research 2. Swiss Multiple Sclerosis Society</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Selmaj</surname><given-names>Krzysztof W.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Genzyme,Biogen,Novartis,Synthon, Roche, Receptos, TEVA, Merck, Celgene, Bayer</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker for Biogen, Novartis, TEVA, Bayer, Roche, Receptos, Genzyme, Travel to AAN 2016 Merck</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Neuroimmunology - member of editorial board - 1994 now. Multiple Sclerosis and Demyelinating Disorders - member of editorial board sinbce 2015</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1)Genzyme 2) Novartis 3) Biogen 4) Roche 5)Synthon 6)Merck 8) Teva</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>1) Novartis 2) Merck 3) Biogen 4) Bayer 5)Genzyme</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Research grant from National Research Center (Poland)and from National Center for Research and Development (Poland)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Traboulsee</surname><given-names>Anthony</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>A. Traboulsee reports receiving consulting fees from Biogen, Novartis, Roche, Sanofi Genzyme, Serono, and Teva Innovation;</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>A Traboulsee has been a principal investigator on clinical trials funded by Roche and Sanofi Genzyme.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Canadian Institute for Health Research, Principal Investigator 2012-2017</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Compston</surname><given-names>D. Alastair S.</given-names></name><degrees>PhD, FRS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Scientific advisory board for Genzyme (a Sanofi company)</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Travel paid for speaking engagements for Genzyme; honoraria paid into departmental budget and (from 2014) for personal use</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>IL-21 as a biomarker of autoimmunity after alemtuzumab</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Genzyme (2) Bayer Schering</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Genzyme</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>(1) Genzyme has made gifts to the University of Cambridge</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Genzyme (2) Bayer Schering</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Medical Research COuncil</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Margolin</surname><given-names>David H.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Treatment of Multiple Sclerosis (MS). Describes dosing regimens for alemtuzumab (Lemtrada).</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Sanofi Genzyme, Global Project Head, 13 years (full- time)</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>(1) Genzyme Corp. (100%), 13 years</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Sanofi Genzyme.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>(1) Sanofi (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales.</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>(1) Sanofi, 13 years. (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales. (Note: Author was not technically an investigator, but participated in the research as Sponsor's medical monitor.) Stock/Stock Options, Medical Equipment &amp; Materials: (1) Sanofi, 13 years. (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Thangavelu</surname><given-names>Karthinathan</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Commercial Entity: I am a current employee of Genzyme Corp. Position: Senior Director, Biostatistics Years: Employed since 22 Sept. 2014.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>Yes, I own stocks of Sanofi (parent company of Genzyme), linked with my employment at Sanofi. I own these stocks since 2016.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Claudio E.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Sanofi Genzyme, Global Safety Officer, 1.3 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Jody</surname><given-names>Darlene</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Sanofi; Head Global Medical Affairs, MS and Immunology,2010-present</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hogan</surname><given-names>Richard J.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Envision Pharma Group, medical writer, 11 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Xenopoulos</surname><given-names>Panos</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Envision Pharma Group, Medical Writer, 2 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Panzara</surname><given-names>Michael A.</given-names></name><degrees>MD, MPH</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Sanofi Genzyme, Head, MS, Neurology, and Ophthalmology Development, from October 2009 to July 2016. Currently employed by Wave Life Sciences, an entitity not related to this manuscript.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Coles</surname><given-names>Alasdair J.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>I have recieved speaker honoraria from Genzyme (a Sanofi company)</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>(1) IL-21 as a marker of autoimmunity after alemtuzumab treatment</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>2016 A randomised placebo-controlled trial of immunotherapy in patients with psychosis associated with anti-neuronal membrane antibodies (SINAPPS 2). Medical Research Council. (2,466,231 fEC) with Co-PI: Peter Jones and Co-applicants: Belinda Lennox, Mike Zandi and James Wason.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>2014 A feasibility study of immunotherapy in antibody- associated psychosis. The Stanley Medical Research Institute (284,176) RG77862 2015 Imaging cerebral metabolism in multiple sclerosis using hyperpolarised carbon. Multiple Sclerosis Society (39,900) as Co-PI (Ferdia Gallagher is PI) 2015 Does early treatment prevent progression? Long term follow-up of alemtuzumab patients. Multiple Sclerosis Society (92,613) RG79876</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>2). Have give expert witness in the past, and possibly in the future, on patents surrounding copaxone and fingolimod as a treatment of multiple sclerosis. Non-financial disclosures: I chair the MS advisory group of the Association of British Neurologists</p></list-item></list></p></author-comment><on-behalf-of>On behalf of CARE-MS I and CAMMS03409 Investigators</on-behalf-of></contrib><aff>From the Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Havrdova: <email>eva.havrdova@lf1.cuni.cz</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Coinvestigators are listed at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004313">Neurology.org</ext-link>. </plain></SENT>
</text></p></fn><fn fn-type="financial-disclosure"><p><text><SENT sid="2" pm="."><plain>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004313">Neurology.org</ext-link> for full disclosures. </plain></SENT>
<SENT sid="3" pm="."><plain>Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. </plain></SENT>
<SENT sid="4" pm="."><plain>The Article Processing Charge was funded by Sanofi. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><day>12</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>9</month><year>2017</year></pub-date><volume>89</volume><issue>11</issue><fpage>1107</fpage><lpage>1116</lpage><history><date date-type="received"><day>09</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2016762211.pdf"/><abstract><sec><title><text><SENT sid="5" pm="."><plain>Objective: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="7" pm="."><plain>Methods: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Alemtuzumab-treated patients received treatment courses at baseline and 12 months later; after the core study, they could enter an extension (NCT00930553) with as-needed alemtuzumab retreatment for relapse or MRI activity. </plain></SENT>
<SENT sid="9" pm="."><plain>Assessments included annualized relapse rate (ARR), 6-month confirmed disability worsening (CDW; ≥1-point Expanded Disability Status Scale [EDSS] score increase [≥1.5 if baseline EDSS = 0]), 6-month confirmed disability improvement (CDI; ≥1-point EDSS decrease [baseline score ≥2.0]), no evidence of disease activity (NEDA), brain volume loss (BVL), and adverse events (AEs). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Results: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>Most alemtuzumab-treated patients (95.1%) completing CARE-MS I enrolled in the extension; 68.5% received no additional alemtuzumab treatment. </plain></SENT>
<SENT sid="12" pm="."><plain>ARR remained low in years 3, 4, and 5 (0.19, 0.14, and 0.15). </plain></SENT>
<SENT sid="13" pm="."><plain>Over years 0–5, 79.7% were free of 6-month CDW; 33.4% achieved 6-month CDI. </plain></SENT>
<SENT sid="14" pm="."><plain>Most patients (61.7%, 60.2%, and 62.4%) had NEDA in years 3, 4, and 5. </plain></SENT>
<SENT sid="15" pm="."><plain>Median yearly BVL improved over years 2–4, remaining low in year 5 (years 1–5: −0.59%, −0.25%, −0.19%, −0.15%, and −0.20%). </plain></SENT>
<SENT sid="16" pm="."><plain>Exposure-adjusted incidence rates of most AEs declined in the extension relative to the core study. </plain></SENT>
<SENT sid="17" pm="."><plain>Thyroid disorder incidences peaked at year 3 and subsequently declined. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="18" pm="."><plain>Conclusions: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="19" pm="."><plain>Based on these data, alemtuzumab provides durable efficacy through 5 years in the absence of continuous treatment, with most patients not receiving additional courses. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="20" pm="."><plain>ClinicalTrials.gov identifier: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="21" pm="."><plain>NCT00530348; NCT00930553. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="22" pm="."><plain>Classification of evidence: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="23" pm="."><plain>This study provides Class III evidence that alemtuzumab durably improves efficacy outcomes and slows BVL in patients with RRMS. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group><funding-source>Sanofi and Bayer HealthCare Pharmaceuticals</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><text><SENT sid="24" pm="."><plain>Alemtuzumab (LEMTRADA; Sanofi Genzyme, Cambridge, MA) is a humanized monoclonal antibody that selectively targets CD52, an antigen highly expressed on T and B lymphocytes.1 Binding of alemtuzumab to CD52 results in depletion of circulating T and B cells,2,3 following which a distinct pattern of T- and B-cell repopulation and a shift in cytokines toward a less inflammatory pattern occur. </plain></SENT>
<SENT sid="25" pm="."><plain>Both mechanisms may be relevant to the durable efficacy of this drug.4 </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Compared with the active treatment subcutaneous interferon β-1a (SC IFN-β-1a; Rebif; EMD Serono Inc., Rockland, MA), alemtuzumab significantly reduced the annualized relapse rate (ARR) in patients with active relapsing-remitting MS (RRMS) who either were treatment-naive (phase 2 CAMMS223 study [NCT00050778]5 and phase 3 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis [CARE-MS] I study [NCT00530348])6 or had an inadequate response (≥1 relapse) to prior therapy (phase 3 CARE-MS II study [NCT00548405]).7 In CAMMS223 and CARE-MS II, alemtuzumab also increased proportions of patients who were free of 6-month confirmed disability worsening (CDW).5,7 Alemtuzumab increased proportions with no evidence of disease activity (NEDA) in the 2-year phase 3 CARE-MS studies6,7 and reduced brain volume loss (BVL) in all 3 clinical trials, compared with SC IFN-β-1a.5–7 The most common adverse events (AEs) with alemtuzumab were infusion-associated reactions (IARs); autoimmune AEs were also associated with treatment.5–7 Based on the positive benefit-risk profile demonstrated in these trials, alemtuzumab is currently licensed in over 60 countries worldwide for treatment of adults with RRMS8,9 and is the only approved treatment that does not require continuous dosing to provide durable efficacy in patients with this disease. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>We report interim results through 3 years of an extension study (NCT00930553) in patients who received alemtuzumab during the core CARE-MS I trial, constituting a total of 5 years of follow-up from CARE-MS I enrollment. </plain></SENT>
</text></p><SecTag type="METHODS"><sec sec-type="methods" id="s1"><title><text><SENT sid="28" pm="."><plain>METHODS </plain></SENT>
</text></title><sec id="s1-1"><title><text><SENT sid="29" pm="."><plain>Patients and procedures for CARE-MS I core study. </plain></SENT>
</text></title><p><text><SENT sid="30" pm="."><plain>The study design for the 2-year CARE-MS I core study has been published previously.6 Briefly, CARE-MS I was a randomized, rater-blinded, active-controlled, head-to-head trial of alemtuzumab compared with SC IFN-β-1a in patients who were treatment-naive and had active RRMS (≥2 relapses in the previous 2 years and ≥1 relapse in the prior year). </plain></SENT>
</text></p></sec><sec id="s1-2"><title><text><SENT sid="31" pm="."><plain>Procedures for the extension study. </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>This analysis reports findings from alemtuzumab-treated patients who completed CARE-MS I and continued into the extension, in which they could receive additional alemtuzumab courses (each 12 mg/d IV on 3 consecutive days) upon evidence of MS disease activity (and ≥48 weeks since the prior course). </plain></SENT>
<SENT sid="33" pm="."><plain>Eligibility criteria for retreatment were ≥1 protocol-defined relapse or ≥2 new/enlarging T2 hyperintense and/or gadolinium (Gd)-enhancing brain or spinal cord lesions on MRI. </plain></SENT>
<SENT sid="34" pm="."><plain>Retreatment-disqualifying criteria included, but were not limited to, pregnancy, diagnosis of immune thrombocytopenia (ITP) or other immune cytopenia, and history of malignancy (except basal cell carcinoma) or antiglomerular basement membrane disease. </plain></SENT>
<SENT sid="35" pm="."><plain>The decision on whether to initiate retreatment in eligible patients was left to the treating physician and patient, as was the decision to provide another licensed disease-modifying therapy (DMT). </plain></SENT>
</text></p></sec><sec id="s1-3"><title><text><SENT sid="36" pm="."><plain>Efficacy assessments and endpoints. </plain></SENT>
</text></title><p><text><SENT sid="37" pm="."><plain>Relapse events required objective signs on examination, lasting ≥48 hours, and were confirmed by the investigator. </plain></SENT>
<SENT sid="38" pm="."><plain>The Expanded Disability Status Scale (EDSS) was assessed quarterly and for evaluation of suspected relapses by raters blinded to previous treatment assignment and treatment history throughout the extension. </plain></SENT>
<SENT sid="39" pm="."><plain>Annual MRI scans were assessed by blinded imaging specialists at NeuroRx Research (Montréal, Canada; for lesion-based analyses) and the Cleveland Clinic MS MRI Analysis Center (Cleveland, OH; for brain parenchymal fraction [BPF] analysis). </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>Clinical efficacy endpoints evaluated over years 0–5 included the following: ARR; proportion of relapse-free patients; 6-month CDW (≥1.0-point EDSS score increase from core study baseline [≥1.5 if baseline EDSS score = 0]; formerly termed sustained accumulation of disability10); mean change from baseline EDSS score; proportions of patients with EDSS scores that were improved (≥1.0-point decrease), worsened (≥1.0-point increase), or stable (≤0.5-point change) compared with baseline; and 3-, 6-, or 12-month confirmed disability improvement (CDI; ≥1.0-point decrease from core study baseline EDSS score, in patients with baseline EDSS scores ≥2.0). </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>MRI lesion outcomes examined over years 0–5 included proportions of patients with Gd-enhancing, new/enlarging T2 hyperintense, and new nonenhancing T1 hypointense lesions. </plain></SENT>
<SENT sid="42" pm="."><plain>Median percentage BVL from baseline and per year was calculated. </plain></SENT>
</text></p><p><text><SENT sid="43" pm="."><plain>NEDA was evaluated annually and cumulatively (sustained NEDA over years 3–5). </plain></SENT>
<SENT sid="44" pm="."><plain>NEDA was defined as no evidence of clinical disease activity (absence of both relapses and 6-month CDW) and no evidence of MRI lesion activity (absence of both new Gd-enhancing and new/enlarging T2 hyperintense lesions). </plain></SENT>
</text></p></sec><sec id="s1-4"><title><text><SENT sid="45" pm="."><plain>Safety monitoring. </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>Safety was evaluated by review of AEs, serious AEs, medical events of interest, and laboratory tests (including thyroid function [at least quarterly], hematology [at least monthly], serum creatinine [monthly], and urinalysis with microscopy [monthly]). </plain></SENT>
<SENT sid="47" pm="."><plain>All safety monitoring procedures continued for 4 years after last alemtuzumab administration, or until study end, whichever occurred later. </plain></SENT>
<SENT sid="48" pm="."><plain>IARs were defined as any AE with onset during infusion or ≤24 hours after the end of infusion. </plain></SENT>
</text></p></sec><sec id="s1-5"><title><text><SENT sid="49" pm="."><plain>Classification of evidence. </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>This analysis evaluates the long-term efficacy and safety of alemtuzumab and provides Class III evidence that alemtuzumab improves ARR, MRI lesion outcomes, and BVL over 5 years in treatment-naive patients with active RRMS and that high proportions of patients achieve NEDA. </plain></SENT>
<SENT sid="51" pm="."><plain>These effects were observed in the absence of continuous treatment and with most (68.5%) patients receiving no alemtuzumab retreatment through 5 years. </plain></SENT>
</text></p></sec><sec id="s1-6"><title><text><SENT sid="52" pm="."><plain>Statistical analysis. </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>Analyses were based on available data (without imputation) on all alemtuzumab 12 mg patients with up to 5 years of follow-up from first dose in CARE-MS I, with an interim cutoff date of October 4, 2014, in the extension. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>ARR was estimated using negative binomial regression with robust variance estimation and covariate adjustment for the geographic region. </plain></SENT>
<SENT sid="55" pm="."><plain>Proportions of patients with 6-month CDW or 3-, 6-, or 12-month CDI were estimated with the Kaplan-Meier method. </plain></SENT>
<SENT sid="56" pm="."><plain>Percentage of patients with improvement, stability, or worsening from the baseline EDSS score was reported. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>Safety data were reported as incidences (percentage of patients with ≥1 event) and exposure-adjusted incidence rates (EAIRs) per 100 patient-years ([number of patients with specific event divided by total annual exposure-time among patients at risk of initial occurrence of the event] × 100) in the reported time cohorts.11 Autoimmune AEs were reported using time of first AE occurrence over total follow-up time (0–5 years). </plain></SENT>
</text></p></sec><sec id="s1-7"><title><text><SENT sid="58" pm="."><plain>Standard protocol approvals, registrations, and patient consents. </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>This trial is registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT00530348; NCT00930553). </plain></SENT>
<SENT sid="60" pm="."><plain>All procedures were approved by local institutional ethics review boards of participating sites. </plain></SENT>
<SENT sid="61" pm="."><plain>Patients provided written informed consent. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s2"><title><text><SENT sid="62" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="s2-1"><title><text><SENT sid="63" pm="."><plain>Patients. </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>Of the 367 alemtuzumab patients completing CARE-MS I, 349 (95.1%) entered the extension study; of these, 335 (96.0%) remained on study through Month 60 (year 5; figure 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><text><SENT sid="65" pm="."><plain>Patient disposition </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>Disposition schematic includes patient participation from the core CARE-MS I study through the long-term extension study. </plain></SENT>
<SENT sid="67" pm="."><plain>DMTs include fingolimod (n = 1), glatiramer acetate (n = 2), interferon β-1a (n = 2), interferon β-1b (n = 3), and natalizumab (n = 1). *The death that occurred in the core study was deemed not related to treatment. </plain></SENT>
<SENT sid="68" pm="."><plain>CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; DMT = disease-modifying therapy. </plain></SENT>
</text></p></caption><graphic xlink:href="NEUROLOGY2016762211FF1"/></fig></SecTag><p><text><SENT sid="69" pm="."><plain>In the core study, alemtuzumab patients received 12 mg on 5 consecutive days at baseline and 3 consecutive days 12 months later. </plain></SENT>
<SENT sid="70" pm="."><plain>In the extension study, 239 (68.5%) alemtuzumab patients received no alemtuzumab retreatment; 341 (97.7%) received no other DMT; and 235 (67.3%) received neither alemtuzumab retreatment nor other DMT. </plain></SENT>
<SENT sid="71" pm="."><plain>Of the 110 patients who received alemtuzumab retreatment (table e-1 at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004313">Neurology.org</ext-link>), 77 (70.0%), 28 (25.5%), and 5 (4.5%) received a total of 1, 2, and 3 alemtuzumab retreatment courses, respectively, over years 3–5. </plain></SENT>
<SENT sid="72" pm="."><plain>The most common reason given by investigators for alemtuzumab retreatment was relapse (51.0% of retreatment courses for which a reason was provided), followed by MRI lesion activity (25.9%), and combined relapse and MRI lesion activity (23.1%). </plain></SENT>
</text></p></sec><sec id="s2-2"><title><text><SENT sid="73" pm="."><plain>Efficacy. </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>ARR remained low during the extension, similar to that in the core study (figure 2A).6 Mean EDSS score changes from core study baseline were improvements (i.e., reductions) at year 2 (−0.16), at year 3 (−0.10), at year 4 (−0.09), and 0.00 at year 5. </plain></SENT>
<SENT sid="75" pm="."><plain>Compared with core study baseline, 60.0% of patients at year 5 showed stable EDSS scores; 22.2% showed improved scores (≥1-point decrease) and 17.8% showed worsened scores (≥1-point increase; figure 2B). </plain></SENT>
<SENT sid="76" pm="."><plain>Over 5 years, 79.7% (95% CI 75.1%–83.6%) of patients were free of 6-month CDW, and 33.4% (95% CI 27.5%–40.1%) achieved 6-month CDI (figure 2C). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><text><SENT sid="77" pm="."><plain>Clinical efficacy and disease activity outcomes over 5 years in alemtuzumab patients </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>(A) ARR over 5 years in alemtuzumab patients. </plain></SENT>
<SENT sid="79" pm="."><plain>Results are shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. </plain></SENT>
<SENT sid="80" pm="."><plain>A post hoc analysis revealed no statistically significant difference between ARRs in individual extension years (years 3, 4, and 5) and the ARR in years 0–2. </plain></SENT>
<SENT sid="81" pm="."><plain>(B) EDSS score change in alemtuzumab patients over 5 years. </plain></SENT>
<SENT sid="82" pm="."><plain>Proportion of patients with improved (≥1.0-point decrease), stable (≤0.5-point change), or worsened (≥1.0-point increase) EDSS scores at year 5 compared with core study baseline. </plain></SENT>
<SENT sid="83" pm="."><plain>EDSS score changes are shown for all patients who received alemtuzumab 12 mg in the core study and enrolled in the extension. </plain></SENT>
<SENT sid="84" pm="."><plain>(C) Proportion of alemtuzumab patients with 3-, 6-, or 12-month CDI over 5 years. </plain></SENT>
<SENT sid="85" pm="."><plain>Kaplan-Meier analysis of time to 3-, 6-, or 12-month CDI is shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. </plain></SENT>
<SENT sid="86" pm="."><plain>(D) Proportion of alemtuzumab patients with NEDA over 5 years. </plain></SENT>
<SENT sid="87" pm="."><plain>Results are shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. *Baseline percentage of patients Gd-enhancing lesion-free: 54%. </plain></SENT>
<SENT sid="88" pm="."><plain>ARR = annualized relapse rate; CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CDI = confirmed disability improvement; CDW = confirmed disability worsening; EDSS = Expanded Disability Status Scale; Gd = gadolinium; NEDA = no evidence of disease activity. </plain></SENT>
</text></p></caption><graphic xlink:href="NEUROLOGY2016762211FF2"/></fig></SecTag><p><text><SENT sid="89" pm="."><plain>Most alemtuzumab-treated patients were free of clinical disease activity or MRI lesion activity during each extension year and most also attained NEDA (figure 2D). </plain></SENT>
<SENT sid="90" pm="."><plain>Cumulatively over years 3–5, most patients showed no clinical (65.3%) or MRI lesion (53.8%) activity, and 39.5% attained sustained NEDA. </plain></SENT>
<SENT sid="91" pm="."><plain>During each extension year, most patients were free of new T1 hypointense lesions (year 3, 89.2%; year 4, 85.4%; year 5, 85.4%). </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>The rate of yearly BVL continued to decrease after the core study and seemed to stabilize in years 3, 4, and 5 (figure 3). </plain></SENT>
<SENT sid="93" pm="."><plain>Median cumulative BPF change from baseline to year 5 was –1.352%. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><text><SENT sid="94" pm="."><plain>Brain volume loss over 5 years in alemtuzumab patients </plain></SENT>
</text></title><p><text><SENT sid="95" pm="."><plain>Median yearly percentage change in BPF is shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. </plain></SENT>
<SENT sid="96" pm="."><plain>BPF = brain parenchymal fraction; CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis. </plain></SENT>
</text></p></caption><graphic xlink:href="NEUROLOGY2016762211FF3"/></fig></SecTag><p><text><SENT sid="97" pm="."><plain>Further analyses evaluated outcomes among the 175 patients who achieved NEDA in year 2 and received no alemtuzumab retreatment after the initial 2 courses and no other DMT (figure e-1A). </plain></SENT>
<SENT sid="98" pm="."><plain>Most patients achieved NEDA in each year of the extension and 60.8% attained NEDA through years 2–5, reflecting high proportions of relapse-free, 6-month CDW-free and new Gd-enhancing and T2 hyperintense lesion-free patients (figure e-1B); this cohort with sustained NEDA demonstrated slowing of median annual BVL (figure e-2). </plain></SENT>
</text></p></sec><sec id="s2-3"><title><text><SENT sid="99" pm="."><plain>Safety. </plain></SENT>
</text></title><p><text><SENT sid="100" pm="."><plain>AEs occurring in alemtuzumab-treated patients throughout the core and extension studies (up to the cutoff date; 1767.7 patient-years over 5-year follow-up) are summarized in tables 1 and 2 and table e-2. </plain></SENT>
<SENT sid="101" pm="."><plain>The EAIR for overall AEs was lower in the extension (years 3–5, 133.6) than in the core study (years 0–2, 705.2). </plain></SENT>
<SENT sid="102" pm="."><plain>Serious AE incidence remained low over 5 years. </plain></SENT>
<SENT sid="103" pm="."><plain>Most AEs (96.9%) in years 3–5 were mild to moderate in severity. </plain></SENT>
<SENT sid="104" pm="."><plain>No AEs led to study withdrawal in the extension. </plain></SENT>
<SENT sid="105" pm="."><plain>One death, reported previously, occurred during the extension (in year 3), due to sepsis that developed in the setting of pancytopenia and was judged by the investigator to be treatment-related.6 </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="106" pm="."><plain>AEs through year 5 of the extension in patients treated with alemtuzumab 12 mg </plain></SENT>
</text></p></caption><graphic xlink:href="NEUROLOGY2016762211TT1"/></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="107" pm="."><plain>IAR events through year 5 in patients treated with alemtuzumab 12 mg </plain></SENT>
</text></p></caption><graphic xlink:href="NEUROLOGY2016762211TT2"/></table-wrap></SecTag><p><text><SENT sid="108" pm="."><plain>IAR incidences in patients receiving alemtuzumab retreatment in the extension were lower than in the core study (table 2). </plain></SENT>
<SENT sid="109" pm="."><plain>No serious IARs occurred during the extension (courses 3, 4, or 5). </plain></SENT>
<SENT sid="110" pm="."><plain>Similar to the core study,6 the most frequently reported IARs with alemtuzumab retreatment in the extension were headache, pyrexia, and rash. </plain></SENT>
<SENT sid="111" pm="."><plain>When IARs were removed from the count of any AEs overall, the EAIR remained lower in the extension (129.2) compared with that in the core study (174.8). </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>Overall incidences and EAIRs of infections over years 3–5 were lower than during the core study (table 1 and table e-2); 99.2% were mild to moderate in severity. </plain></SENT>
<SENT sid="113" pm="."><plain>Infection incidence did not increase with successive alemtuzumab courses (table e-3). </plain></SENT>
<SENT sid="114" pm="."><plain>As in the core study, the most common infection events in the extension were nasopharyngitis, urinary tract infection, upper respiratory tract infection, and herpetic infections (predominantly mucocutaneous). </plain></SENT>
<SENT sid="115" pm="."><plain>The incidence of serious infections remained low; the most frequent was herpes zoster, with a total of 5 cases occurring over years 0–5 (4 were during the extension). </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>The most common autoimmune AEs occurring during the extension were thyroid AEs, which peaked in year 3 and subsequently declined in years 4 and 5 (years 1–5 incidences: 6.4%, 9.6%, 15.3%, 7.6%, and 3.5%; incidence over 5 years was 40.7%). </plain></SENT>
<SENT sid="117" pm="."><plain>Of the thyroid AEs reported in years 3–5, 62.1% were moderate and 27.1% were mild in severity. </plain></SENT>
<SENT sid="118" pm="."><plain>Similar incidences were observed over time for the broader category of thyroid disorders (table 1 and table e-2), which include abnormal thyroid function tests (thyroid-stimulating hormone, free triiodothyronine [T3], free thyroxine [T4]) in addition to investigator-reported thyroid AEs; incidence over 5 years was 45.5%. </plain></SENT>
<SENT sid="119" pm="."><plain>Few serious thyroid AEs were reported. </plain></SENT>
<SENT sid="120" pm="."><plain>As in the core study, the most frequently reported thyroid disorders in the extension were laboratory abnormalities, and clinical hyperthyroidism and hypothyroidism. </plain></SENT>
<SENT sid="121" pm="."><plain>Thirteen thyroidectomies were reported over years 0–5; most patients undergoing thyroidectomies were subsequently maintained on thyroxine. </plain></SENT>
</text></p><p><text><SENT sid="122" pm="."><plain>One new case of ITP was reported during the extension (year 4). </plain></SENT>
<SENT sid="123" pm="."><plain>The patient had a postalemtuzumab history of autoimmune hemolytic anemia that had resolved with treatment 2 years before ITP onset. </plain></SENT>
<SENT sid="124" pm="."><plain>At last follow-up, the patient was receiving oral prednisone for ITP, which was considered resolved several months after the initial event. </plain></SENT>
</text></p><p><text><SENT sid="125" pm="."><plain>There was a single case of nephropathy reported in year 3 (4 months after the third alemtuzumab course). </plain></SENT>
<SENT sid="126" pm="."><plain>The patient presented with hematuria and proteinuria. </plain></SENT>
<SENT sid="127" pm="."><plain>Serum creatinine levels remained normal, but there was weak seropositivity for antiglomerular basement membrane autoantibodies. </plain></SENT>
<SENT sid="128" pm="."><plain>A renal biopsy revealed focal global glomerulosclerosis and changes indicative of membranous nephropathy, but no evidence of antiglomerular basement membrane disease. </plain></SENT>
<SENT sid="129" pm="."><plain>By 39 months after the initial event, following treatment with plasmapheresis, glucocorticosteroids, and cyclophosphamide, serum creatinine levels remained normal, proteinuria was absent, and the patient did not develop kidney failure. </plain></SENT>
</text></p><p><text><SENT sid="130" pm="."><plain>Over 5 years, a total of 6 malignancies were reported in alemtuzumab-treated patients (EAIR of 0.3 per 100 patient-years). </plain></SENT>
<SENT sid="131" pm="."><plain>Two malignancies occurred in the core study (both papillary thyroid carcinomas), and 4 malignancies were reported in years 3–5 (n = 1 each for breast cancer, keratoacanthoma, non–small-cell lung cancer, and micropapillary thyroid carcinoma). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s3"><title><text><SENT sid="132" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>Damage to neurons and axons starts in the earliest stages of MS and is clinically relevant, as it may foreshadow evolution of neurologic disability.12,13 CNS tissue destruction can be quantified by MRI as cerebral atrophy, which is accelerated in patients with MS compared with healthy individuals.14 Thus, to prevent accumulation of permanent neurologic damage, early intervention in MS is important and warranted.15 However, experts have not reached consensus regarding what constitutes appropriate early-stage treatment for patients with adverse prognostic factors (e.g., an early disease course that includes frequent relapses, MRI lesion volume change, or brain atrophy).16–18 Some physicians may initially prescribe a low- to moderate-efficacy therapy and may switch to high-efficacy therapy upon evidence of an inadequate response (e.g., disease activity while on therapy), whereas others favor an individualized approach involving higher-efficacy agents from the outset.19 CARE-MS I compared these approaches in patients with active RRMS and found greater improvements in relapse and MRI outcomes, as well as higher attainment of NEDA, in patients who received alemtuzumab compared with SC IFN-β-1a.6 </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>We show that these findings were extended in the CARE-MS I alemtuzumab treatment arm, with durable improvements in key efficacy outcomes over 5 years, including low ARR and most patients having stable/improved EDSS scores and freedom from 6-month CDW. </plain></SENT>
<SENT sid="135" pm="."><plain>Additionally, more than one-third achieved 6-month CDI. </plain></SENT>
<SENT sid="136" pm="."><plain>This endpoint captures durable and clinically meaningful EDSS score changes in individual patients with preexisting neurologic impairments; improving disability in those patients may lead to better long-term prognosis.20 Our study reports durable improvement in disability by using this stringent outcome measure over several years in a large MS patient cohort. </plain></SENT>
<SENT sid="137" pm="."><plain>Additionally, during each of years 3, 4, and 5, a consistent proportion of about 60% of patients achieved NEDA; when the rigorous goal of sustained NEDA was assessed cumulatively over years 3–5, 40% of patients satisfied this endpoint. </plain></SENT>
<SENT sid="138" pm="."><plain>These effects were observed in the absence of continuous treatment and despite no retreatment in the majority of patients. </plain></SENT>
<SENT sid="139" pm="."><plain>Similar durable efficacy improvements were also shown for patients with active RRMS who had an inadequate response to prior therapy.21 </plain></SENT>
</text></p><p><text><SENT sid="140" pm="."><plain>Previous studies have shown the predictive value of brain atrophy on disability outcomes in the early years after MS diagnosis.18 Treatment effects on brain atrophy and lesion activity correlate with treatment effects on disability and cognitive dysfunction for some therapies.14,18,22–24 No current therapies are known to reverse CNS damage. </plain></SENT>
<SENT sid="141" pm="."><plain>Alemtuzumab slowed the annual rate of BVL over years 3–5. </plain></SENT>
<SENT sid="142" pm="."><plain>Moreover, alemtuzumab-treated patients showed less cumulative atrophy after 5 years (reported in this study) compared with that observed in patients who had received SC IFN-β-1a in the core study and then switched to alemtuzumab in the extension (median BPF changes of −1.352% vs −1.646%, respectively; p = 0.0086),25 illustrating the long-term benefits of early treatment with alemtuzumab. </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>Durable efficacy with alemtuzumab over the 3-year extension follow-up was accompanied by a safety profile consistent with that observed in the core study. </plain></SENT>
<SENT sid="144" pm="."><plain>Overall AEs, including IARs and infections, decreased over time relative to the core study, with a low but persistent risk of herpes zoster reactivation. </plain></SENT>
<SENT sid="145" pm="."><plain>Autoimmune thyroid AEs peaked at year 3 and declined thereafter. </plain></SENT>
<SENT sid="146" pm="."><plain>The rate of malignancies did not increase from the core study through the extension. </plain></SENT>
<SENT sid="147" pm="."><plain>Two cases of papillary thyroid carcinomas were seen in the core study; only 1 new micropapillary thyroid carcinoma event was reported over the next 3 years. </plain></SENT>
<SENT sid="148" pm="."><plain>The apparent rate of thyroid malignancies observed with alemtuzumab in the MS clinical trial program may have been inflated by ascertainment bias owing to a more frequent occurrence of nonmalignant thyroid disorders and their diagnostic workup26 with alemtuzumab than with SC IFN-β-1a. </plain></SENT>
<SENT sid="149" pm="."><plain>These observations relating to safety with alemtuzumab are in contrast to AE rates that have been observed with long-term use of chronically dosed DMTs, in which the known risks associated with a particular agent may increase or remain constant with continued exposure to drug.27–29 With alemtuzumab, because of its unique dosing schedule and lack of continuous treatment, most risks decrease over time. </plain></SENT>
<SENT sid="150" pm="."><plain>Procedures for regular monitoring and management help to maximize the risk-benefit profile. </plain></SENT>
</text></p><p><text><SENT sid="151" pm="."><plain>As is often cited as a limitation of extension studies, the active comparator design of the pivotal CARE-MS trials6,7 was not continued in the extension period, thus precluding long-term direct comparison with another treatment. </plain></SENT>
<SENT sid="152" pm="."><plain>Nonetheless, these 5-year data from patients who were treatment-naive and had a mean disease duration of 2 years upon entry into CARE-MS I demonstrate durable, long-term therapeutic effects on clinical disease activity measures, as well as on more objective measures such as MRI lesion activity and brain atrophy. </plain></SENT>
<SENT sid="153" pm="."><plain>The robustness of our results is supported by the high patient enrollment rate coupled with the unusually high retention rate (&gt;95% through year 5). </plain></SENT>
<SENT sid="154" pm="."><plain>Notably, the latter suggests that the favorable outcomes in our study cannot reflect selective dropout of poor responders. </plain></SENT>
<SENT sid="155" pm="."><plain>The continued use of blinded raters also helped ensure unbiased efficacy analyses. </plain></SENT>
</text></p><p><text><SENT sid="156" pm="."><plain>The sustained responses to alemtuzumab observed over 5 years in our study highlight the value of a durable, high-efficacy therapy in the absence of continuous treatment in patients who may be at high risk of MS-related disability worsening and BVL. </plain></SENT>
<SENT sid="157" pm="."><plain>Risks associated with the therapy are anticipated in advance of treatment, and monitoring procedures for minimizing adverse effects are implemented to maintain a positive risk-benefit profile. </plain></SENT>
</text></p></sec></SecTag>
<SecTag type="SUPPL"><sec sec-type="supplementary-material">
<title><text><SENT sid="158" pm="."><plain>Supplementary Material </plain></SENT>
</text></title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title><text><SENT sid="159" pm="."><plain>Data Supplement </plain></SENT>
</text></title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_89_11_1107__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000004313_Figure_e-1.pdf"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000004313_Figure_e-2.pdf"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004313_e-tables.docx"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title><text><SENT sid="160" pm="."><plain>Coinvestigators </plain></SENT>
</text></title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_89_11_1107_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004313_Coinvestigators.docx"/>
</supplementary-material>
<supplementary-material id="PMC_3" content-type="local-data">
<caption>
<title><text><SENT sid="161" pm="."><plain>Accompanying Editorial </plain></SENT>
</text></title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_89_11_1107_v3_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000004313_1098.pdf"/>
</supplementary-material>
</sec></SecTag>
</body><back><fn-group><SecTag type="SUPPL"><fn fn-type="supplementary-material"><p><text><SENT sid="162" pm="."><plain>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004313">Neurology.org</ext-link> </plain></SENT>
</text></p></fn></SecTag><fn fn-type="other"><p><text><SENT sid="163" pm="."><plain>Editorial, page 1098 </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="164" pm="."><plain>See page 1117 </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>ACKNOWLEDGMENT</title><p><text4fund><text><SENT sid="165" pm="."><plain>Critical review of the manuscript was provided by Darren P. Baker, PhD, Madalina C. Chirieac, MD, MPH, Vladimir Evilevitch, MD, PhD, Maria Melanson, MD, PhD, and Sarah Strattman, MS, of Sanofi. </plain></SENT>
<SENT sid="168" pm="."><plain>Kunio Nakamura, PhD, oversaw BPF analyses and was an employee of the Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, at the time the work was conducted. </plain></SENT>
<SENT sid="169" pm="."><plain>Additional statistical support was provided by Linda Kasten, BS, MA, who received compensation (Sanofi) as an employee of PROMETRIKA, LLC, when the statistical analyses were performed; currently an employee of Biostatistical Consulting, Inc. </plain></SENT>
<SENT sid="170" pm="."><plain>Catherine Pennella, BS, of Sanofi assisted in safety analyses. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="AUTH_CONT"><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">E.H., J.A.C., H.-P.H., E.J.F., G.G., S.S., K.W.S., A.T., D.A.S.C., and A.J.C. contributed to study design, data collection, writing and critical review of the manuscript, and approved the final submission draft. D.L.A. contributed to data collection, writing and critical review of the manuscript, and approved the final submission draft. D.H.M. and M.A.P. contributed to study design, writing and critical review of the manuscript, and approved the final submission draft. C.E.R and D.J. contributed to writing and critical review of the manuscript, and approved the final submission draft. K.T. led statistical support and also contributed to the writing and critical review of the manuscript, and approved the final submission draft. R.J.H. and P.X. provided editorial and medical writing support (assistance in drafting the manuscript, technical editing, copyediting, and responding to reviewers' comments), and approved the final submission draft.</p></sec></SecTag><SecTag type="ACK_FUND"><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding"><text4fund><text><SENT sid="171" pm="."><plain>Supported by Sanofi and Bayer HealthCare Pharmaceuticals. </plain></SENT>
</text></text4fund></p></sec></SecTag><SecTag type="COMP_INT"><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">E. Havrdova reports receiving honoraria and grant support from Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi Genzyme, and Teva, and is supported by Ministry of Education of Czech Republic, project PRVOUK-P26/LF1/4. D.L. Arnold reports receiving compensation for serving as a speaker, consultant, and advisory board participant, and receiving research support from Acorda, Bayer, Biogen, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, MedImmune, Merck Serono, NeuroRx Research, Novartis, Opexa Therapeutics, Receptos, Roche, Sanofi Genzyme, Teva, the Canadian Institutes of Health Research, and the Multiple Sclerosis Society of Canada. J.A. Cohen reports personal compensation for consulting for Genentech, Merck, Novartis, and Receptos and as a coeditor of <italic>Multiple Sclerosis Journal—Experimental, Translational and Clinical</italic>. H.-P. Hartung reports receiving honoraria for consulting and speaking at symposia from Bayer HealthCare, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, and Sanofi Genzyme. E.J. Fox reports receiving consulting fees, honoraria, travel, and research support from Acorda, Bayer HealthCare, Biogen, EMD Serono, Genentech, Novartis, Opexa Therapeutics, Sanofi Genzyme, and Teva. G. Giovannoni reports having served as a consultant or received research support from AbbVie, Bayer HealthCare, Biogen, Canbex Therapeutics, Five Prime Therapeutics, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Oxford PharmaGenesis, Protein Discovery Laboratories, Roche, Sanofi Genzyme, Synthon, Teva, and UCB. S. Schippling reports receiving research grants from Novartis and Sanofi Genzyme; and consulting and speaking fees from Biogen, Merck Serono, Novartis, Sanofi Genzyme, and Teva. K.W. Selmaj reports receiving consulting fees from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Synthon. A. Traboulsee reports receiving consulting fees from Biogen, Novartis, Roche, Sanofi Genzyme, Serono, and Teva Innovation; and has been a principal investigator on clinical trials funded by Roche and Sanofi Genzyme. D.A.S. Compston reports receiving consulting fees and grant support from Genzyme and lecture fees from Bayer Schering Pharma on behalf of the University of Cambridge; and personal remuneration for lecture fees from Genzyme from July 2014. D.H. Margolin, K. Thangavelu, C.E. Rodriguez, and D. Jody report receiving personal compensation as an employee of Sanofi. R.J. Hogan and P. Xenopoulos report receiving personal compensation as an employee of Evidence Scientific Solutions. M.A. Panzara received personal compensation as an employee of Sanofi during study conduct and analysis and during preparation of the manuscript. A.J. Coles reports receiving consulting fees, lecture fees, and institutional grant support from Sanofi Genzyme. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004313">Neurology.org</ext-link> for full disclosures.</p></sec></SecTag><SecTag type="ABBR"><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G2">ARR</term><def><p>annualized relapse rate</p></def></def-item><def-item><term id="G3">BPF</term><def><p>brain parenchymal fraction</p></def></def-item><def-item><term id="G4">BVL</term><def><p>brain volume loss</p></def></def-item><def-item><term id="G5">CDI</term><def><p>confirmed disability improvement</p></def></def-item><def-item><term id="G6">CDW</term><def><p>confirmed disability worsening</p></def></def-item><def-item><term id="G7">DMT</term><def><p>disease-modifying therapy</p></def></def-item><def-item><term id="G8">EAIR</term><def><p>exposure-adjusted incidence rate</p></def></def-item><def-item><term id="G9">EDSS</term><def><p>Expanded Disability Status Scale</p></def></def-item><def-item><term id="G10">IAR</term><def><p>infusion-associated reaction</p></def></def-item><def-item><term id="G11">ITP</term><def><p>immune thrombocytopenia</p></def></def-item><def-item><term id="G12">NEDA</term><def><p>no evidence of disease activity</p></def></def-item><def-item><term id="G13">RRMS</term><def><p>relapsing-remitting MS</p></def></def-item><def-item><term id="G14">SC IFN-β-1a</term><def><p>subcutaneous interferon β-1a</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="172" pm="."><plain>1.WeberMS, HemmerB Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ 2010;51:115–126.19582406 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="173" pm="."><plain>2.HuY, TurnerMJ, ShieldsJ, et al Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260–270.19740383 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="174" pm="."><plain>3.RaoSP, SanchoJ, Campos-RiveraJ, et al Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012;7:e39416.22761788 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="175" pm="."><plain>4.CoxAL, ThompsonSA, JonesJL, et al Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35:3332–3342.16231285 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="176" pm="."><plain>5.CAMMS223 Trial Investigators, ColesAJ, CompstonDA, et al Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786–1801.18946064 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="177" pm="."><plain>6.CohenJA, ColesAJ, ArnoldDL, et al Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819–1828.23122652 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="178" pm="."><plain>7.ColesAJ, TwymanCL, ArnoldDL, et al Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–1839.23122650 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="179" pm="."><plain>8.LEMTRADA [Summary of Product Characteristics] [online]. Oxford, United Kingdom: Genzyme Therapeutics, Ltd Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf">ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf</ext-link>. </plain></SENT>
<SENT sid="180" pm="."><plain>Accessed May 30, 2014. </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="181" pm="."><plain>9.LEMTRADA (Alemtuzumab), for Intravenous Injection [Prescribing Information]. Cambridge, MA: Genzyme Corporation; 2014. </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="182" pm="."><plain>10.LublinFD, ReingoldSC, CohenJA, et al Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–286.24871874 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="183" pm="."><plain>11.LiuGF, WangJ, LiuK, SnavelyDB Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials. Stat Med 2006;25:1275–1286.16138360 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="184" pm="."><plain>12.ComiG Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31:1142–1157.19695384 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="185" pm="."><plain>13.RushCA, MacLeanHJ, FreedmanMS Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2015;11:379–389.26032396 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="186" pm="."><plain>14.ZivadinovR, RederAT, FilippiM, et al Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136–144.18606968 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="187" pm="."><plain>15.Multiple Sclerosis Therapy Consensus Group (MSTCG), WiendlH, ToykaKV, et al Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449–1463.19005625 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="188" pm="."><plain>16.ScalfariA, NeuhausA, DegenhardtA, et al The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914–1929.20534650 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="189" pm="."><plain>17.FisnikuLK, BrexPA, AltmannDR, et al Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808–817.18234696 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="190" pm="."><plain>18.PopescuV, AgostaF, HulstHE, et al Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84:1082–1091.23524331 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="191" pm="."><plain>19.RieckmannP Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009;277(suppl 1):S42–S45.19200866 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="192" pm="."><plain>20.ColesAJ, FoxE, VladicA, et al Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338–348.21397567 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="193" pm="."><plain>21.FoxEJ, ArnoldDL, CohenJA, et al Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years. Mult Scler 2015;21(suppl 11):P1102. </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="194" pm="."><plain>22.FisherE, RudickRA, CutterG, et al Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373–377.11212131 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="195" pm="."><plain>23.JacobsenC, HagemeierJ, MyhrKM, et al Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014;85:1109–1115.24554101 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="196" pm="."><plain>24.SormaniMP, ArnoldDL, De StefanoN Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43–49.24006277 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="197" pm="."><plain>25.BarkhofF, CohenJA, ColesA, et al RRMS patients switching from SC IFNB-1a to alemtuzumab in the CARE-MS I and II extension study have a reduced rate of brain volume loss (P6.183). Neurology 2016;86(suppl):16. </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="198" pm="."><plain>26.SchneiderDF, ChenH New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin 2013;63:374–394.23797834 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="199" pm="."><plain>27.ButzkuevenH, KapposL, PellegriniF, et al Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190–1197.24532785 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="200" pm="."><plain>28.O'ConnorP, GoodmanA, KapposL, et al Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014;83:78–86.24898925 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="201" pm="."><plain>29.BloomgrenG, RichmanS, HotermansC, et al Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–1880.22591293 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
